

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jia Yao Holdings Limited

嘉耀控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 01626)

VOLUNTARY ANNOUNCEMENT UPDATE ON BUSINESS DEVELOPMENT

This announcement is made by Jia Yao Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to provide the shareholders and potential investors of the Company with an update on the Group’s latest business development.

The Group has been consistently paying attention to fields related to health and biomedicine in recent years. The Board is pleased to announce that the Group has officially commenced Cannabidiol (“**CBD**”) related business in April 2026. Currently, the Group is primarily engaged in the procurement and export of CBD from China, with products mainly sold to skincare, daily chemical and pharmaceutical enterprises in Europe and North America. The Group has established a specialized operation team responsible for this business, with core members possessing relevant industry experience.

The Group strictly abides by relevant laws and regulations and conducts its business under the premise of legal compliance. As of the date of this announcement, the Group has obtained the necessary qualifications and permits for the relevant business. In accordance with relevant Chinese regulatory requirements, the Group has obtained the “Registration Certificate for Operation of Non-drug Precursor Chemicals”. Regarding the existing export business, the Group has applied for and

obtained the “Export License for Dual-Use Items and Technologies”. The Group has become one of the few enterprises in China currently capable of legally engaging in CBD procurement and export business. Furthermore, the Group will continue to closely monitor the changes in laws and regulations regarding CBD in various relevant jurisdictions to ensure continuous business compliance.

At this stage, the Group primarily utilizes its supply chain advantages to provide CBD at a competitive price to overseas markets. As of the date of this announcement, although the relevant business is in an early stage of development, substantive trade contracts have been signed, and actual sales revenue and collections have been generated.

Building upon its deep cultivation of existing European and Southeast Asian markets, the Group plans to gradually explore the feasibility of extending into downstream terminal products (such as beauty and personal care, pet health care, etc.). The Group will also continue to invest in research on relevant applications, including plans to explore product R&D cooperation with academic institutions.

Given the medical application value of CBD has been confirmed by international authoritative medical journals, and several countries and regions worldwide have relaxed policies related to CBD medical applications, the Board believes that the market demand is expected to continue growing. The Group’s relevant business is expected to make a positive contribution to the Company’s future cash flow and profit growth.

By order of the Board
JIA YAO HOLDINGS LIMITED
Yang Yoong An
Chairman and Executive Director

Hong Kong, 21 April 2026

As at the date of this announcement, the Board comprises Mr. Yang Yoong An (Chairman) and Li Lin as executive Directors, Mr. Yang Fan as non-executive Director and Mr. Gong Jinjun, Ms. Guo Wei and Mr. Wang Ping as independent non-executive Directors.